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1. Introduction 
 
Sugar-nucleoside diphosphates (sugar-nucleotides) are imperative to carbohydrate 
metabolism and glycoconjugate biosynthesis. They are composed of an activated sugar donor 
that is glycosylated onto a diverse range of acceptors,1 typified by glycosyltransferase 
catalysed processes for the assembly of glycosides and oligo- or poly-saccharides.2 They are 
of considerable interest as carbohydrate-based tools for the study of glycoconjugate 
biosynthesis and for their potential as enzyme inhibitors in therapeutic intervention 
strategies.3 In addition, they are requisite for unambiguous biochemical assay development 
and for the provision of structurally defined homogenous analytical standards. Thorough 
reviews concerning chemical4 and enzymatic5 methods for sugar-nucleotide synthesis were 
completed almost a decade ago along with recent reviews of nucleotide,6 pyrophosphate 
analogue7 and phosphate ester/anhydride synthesis.7,8 We seek here to update this exciting 
branch of glycoscience and present a current state of the art (2009-onwards) for the chemical 
synthesis of natural and mimetic sugar-nucleotides. 
 
2. Synthetic approaches towards sugar-nucleotides 
 
Sugar-nucleotide’s are structurally diverse, consisting of a sugar linked to a 
nucleoside diphosphate (sugar nucleoside monophosphates, such as CMP-sialic acid, are not 
covered here). Figure 1 illustrates a generic sugar-nucleotide, alongside two common 
methodologies for their chemical synthesis. Disconnection approaches have focused on the 
phosphate linkage between the sugar and nucleoside components, most commonly favouring 
pyrophosphorylation using a sugar-1-phosphate (sugar-1-P) and an activated nucleoside 
monophosphate (NMP) (Figure 1, pathway b). Sugar-nucleotides have also been prepared via 
direct glycosylation using a nucleoside diphosphate (NDP) with a glycosyl donor4,9 (Figure 1, 
pathway a).  
In animal cells the most commonly occurring sugar-nucleotides utilise a uridine or 
guanidine-containing nucleoside diphosphate (UDP or GDP) along with a sugar; this includes 
aldopentose (UDP-Xyl), aldohexose (UDP-Glc, UDP-Gal), aldohexosamine (UDP-GlcNAc, 
UDP-GalNAc) and uronic acid (UDP-GlcA) components. These common mammalian 
examples are illustrated in Figure 1 c) , alongside some examples found in bacteria, such as 
GDP-ManA, UDP-Galf and dTDP-L-Rha. 
In recent years, chemical approaches to synthesise sugar-nucleotides have favoured a 
PV-PV pyrophosporylation coupling, alongside effective PV-PIII coupling chemistries.10 In this 
mini-review we first discuss recent advances towards the synthesis of anomeric sugar-1-Ps, 
followed by diphosphate-forming approaches to the parent sugar-nucleotide. 
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c) representative mammalian and bacterial sugar-nucleotides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Approaches to sugar-nucleotides: a) direct glycosylation strategy with a nucleoside diphosphate and 
glycosyl donor b) pyrophosphorylation using a sugar-1-P and nucleoside monophosphate. LG = leaving group, 
R = H/OH, Base = heterocycle (C, U, T, G, A), X = phosphate or diphosphate counter ion c) representative 
examples of common mammalian and bacterial sugar-nucleotides. 
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3. Synthesis of anomeric sugar-1-phosphates 
 
3.1. α-linked sugar-1-phosphates 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Overview of recent strategies used for the synthesis of α-linked sugar-1-P’s. Each red numbered 
option is subsequently referred to in the discussion.  
 
Figure 2 illustrates some of the different approaches that have been introduced since 
2009 for the synthesis of sugar-1-Ps with an α-anomeric configuration. This constitutes an 
important development within the field, whereby a range of conditions, high yields and good 
anomeric selectivity now compliment the diverse substrate scope that glycosyl-1-Ps represent 
for native and mimetic sugar-nucleotide access and evolves from more traditional methods, 
such as Macdonald phosphorylation.11 Generally beginning from a hemi-acetal, sugar-1-P’s 
can be obtained from several different phosphorous sources, either directly at the PV 
oxidation level or using a PIII approach, followed by oxidation. These are discussed first, 
followed by access from alternative anomeric substituents. 
Janda et al.12 synthesised α,β-GalNAz-1-phosphate 1 as part of their approach 
towards UDP-GalNAz (see Scheme 11). The group treated α,β-GalNAz-1-OH with 
salicyl chlorophosphite, followed by aqueous hydrolysis of the resultant cyclic phosphite to 
deliver a PIII species, which was oxidized with I2 to deliver 1 in 62% yield over three steps 
(Figure 2, option 1). Sun and co-workers13 synthesised α-1-phosphates of L-Rha 2 and L-
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6dTal 3 using a two-stage approach again starting at PIII (Figure 2, option 2). Hemi-acetal 
phosphitylation with triimidazole phosphite (PIm3) and subsequent basic hydrolysis 
(Et3N/H2O) delivered sugar-1-H-phosphonate monoesters in 93-95% yield. The 1-H-
phosphonates were then converted to silylated phosphite triesters using 
N,O-bis(trimethylsilyl)acetamaide (BSA), followed by oxidation under basic conditions 
(I2/Et3N) to deliver the PV products in 87-89% yield. The group noted that the basic oxidation 
conditions for the second stage were essential to counter the TMSI generated upon silyl 
phosphite ether cleavage and prevent unwanted degradation of the product.  
Linhardt’s group14 recently reported their chemical synthesis of fluorinated mimetic 
sugar-nucleotides (see Scheme 7), whereby the group accessed the required sugar-1-Ps 
through deprotonation of the hemi-acetal (using LDA) and reaction with the electrophilic PV 
reagent, tetrabenzylpyrophosphate. This furnished the desired α-linked phosphates 4 and 5 in 
very good yields (72% for 4 and 77% for 5) and excellent α-selectivity (Figure 2, option 3).  
Liu et al15 took an alternative approach when synthesizing the glycosyl-1-phosphate 
precursor of GDP-α-D-octose, necessary for elucidation of the biosynthesis of a clinically 
useful antibiotic, Lincomycin A. Using a hemi-acetal as the nucleophile, the group employed 
the phosphoramidite reagent iPr2N(OBn)2 and 1-H-tetrazole activation, followed by oxidation 
of the phosphite to PV, using m-CPBA, delivering α-D-octose-1-phosphate 6 in 23% yield, 
over three steps (Figure 2, option 4). Meier and co-workers16 also used the same 
phosphoramidite reagent in combination with 4,5-dicyanoimidazole (DCI), followed by 
oxidation, to synthesise a series of protected 2-fluorinated sugar-1-P’s 7-9 in good yields (57-
83%, Scheme 1) and, in the case of mannose derivative 9, with complete α-selectivity. 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of 2-F substituted Gal- Glc- and Man-1-P derivatives 7-9. i) iPr2N(OBn)2, DCI, DCM, 16 h 
ii) m-CPBA, 4 h.  
 
The Liu group17 utilised the PV reagent dibenzyl phosphorochloridate to achieve 
anomeric phosphorylation in their synthesis of fluorinated sugar-nulceotide mimetics (see 
Schemes 8 and 9), which they achieved using an oxidative chlorination step, combining PIII 
dibenzyl-1-H-phosphonate and N-chlorosuccinamide (Figure 2, option 5). Starting from the 
anomeric hemi-acetal, deprotonation with nBuLi and subsequent reaction with the PV 
phosphorochloridate afforded the desired Bn-protected-1-phosphate 10 in 48% yield (2 steps, 
including formation of the phosphorochloridate) and exclusive α-selectivity.  
Zhou’s group18 synthesised a series of O-4-substituted 2,3,6 trideoxy-L-rhodinose-1-
phosphates by first converting the hemi-acetal to the corresponding glycosyl chloride (Figure 
2, option 6). They achieved this using oxalyl chloride, interestingly noting a faster 
decomposition of the chloride for 4-position electron donating substituents, such as OTBS, 
and rationalising this as contributing a destabilising effect upon the oxocarbenium ion 
intermediate. Phosphorylation was effected using tetra-N-butylammonium hydrogen 
phosphate for nucleophilic substitution in acceptable yields (35-48%, for 11-13) and 
furnishing α/β mixtures. The group proposed that the anomeric ratio of the product sugar-1-
Ps correlated to the size of the substituent on O-4, with OTBS displaying the lowest 
preference for the β-anomer compared with OMe or OAc. 
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Lowary et al19 recently sought a series of methoxy and deoxy GDP-Man derivatives 
and in doing so explored the substrate tolerance of a GDP-mannose pyrophosphorylase from 
Salmonella enterica towards a selection of non-native mannose sugar 1-Ps. From the ethyl 
thioglycoside the group installed dibenzylphosphate using NIS/AgOTf activation conditions 
and obtained the series of protected Man-1-P derivatives 14-18 in good yields (67-84%, 
Scheme 2). The anomeric stereochemistry for the group’s series of sugar-1-Ps was confirmed 
by the size of the 1JC1-H1 coupling constant, which was 177.9 Hz for 14, consistent with α-
stereochemistry. 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of 2-, 3-, 4-, 6-O-methyl and 6-deoxy protected Man-1-P derivatives 14-18. i) HO-
P(O)(OBn)2, NIS, AgOTf, DCM. 
 
The group also installed α-anomeric phosphates onto protected 2-azido-2-deoxy-α-D-
galactofuranose 19 (Scheme 3).20 Starting from the corresponding glycosyl bromide 
(obtained using TiBr4 from the anomeric acetate) and using protected phosphates (dibenzyl to 
access 2-NHAc species and diallyl to access 2-N3) they obtained good α-selectivity and 
intriguingly noted a higher diastereoselection for the dibenzyl phosphate system (5:1, α:β) vs 
diallyl (3:1, α:β).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthesis of 2-deoxy-α-D-Galf-1-phosphates 20 and 21. i) TiBr4, CH2Cl2, EtOAc, rt, 4 days; ii) HO-
P(O)(OBn)2, Et3N, toluene, rt, 3 h; ii) HO-P(O)(OAll)2, Et3N, toluene, rt, 3 h; iv) Pd/C, H2, Et3N, Ac2O, rt, 3 
days; v) MeOH, H2O, Et3N; vi) Pd(OAc)2, NaOMe, H2O, AcOH, rt, 16 h. 
 
Finally, the Nitz group21 recently introduced a protecting-group-free synthesis of 
glycosyl-1-Ps (Scheme 4). Following β-selective formation of 
N’-glycopyranosylsulfonohydrazide (GSH22) donors in excellent yields, subsequent oxidation 
of the GSH using CuCl2 in the presence of a coordinating ligand (2-methyl-2-oxazoline) and 
nucleophilic phosphoric acid delivered α-enriched-sugar 1-P’s in respectable yields (45-64%) 
across a range of hexoses and, importantly, a disaccharide example in 73% yield. 
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Scheme 4. Phosphorylation using oxidative cleavage of GSH donors. 
3.1. β-linked sugar-1-phosphates 
 
Less accessible by conventional methods, due to their lack of thermodynamic 
anomeric stabilisation, β-linked sugar-1-phosphates are nonetheless required for the 
construction of β-linked sugar-nucleotides; which play critical roles, for example, as donor 
substrates for the biosynthesis of bacterial cell wall and LPS components. Vincent and co-
workers23 reported a novel approach to the synthesis of β-phosphoryl-6-azido mannose 22, 
which can be used in a azide-alkyne cycloaddition reactions (Scheme 5). 
  
 
 
 
 
 
 
Scheme 5. Diallyl chlorophosphate for the synthesis of β-1-phosphate 22. i) DMAP, DCM, 4h. 
 
The group employed the electrophilic PV reagent diallyl chlorophosphate which was 
added slowly (1.6 mL/h) to the lactol nucleophile source, encouraging reaction with the more 
nucleophilic equatorial OH, and delivering 22 in good yield (61%) and excellent β-selectivity 
(1:20, α:β). The regent diallyl chlorophosphate is not commercially available and the authors 
also reported a convenient method for its synthesis and subsequently demonstrated the scope 
of their approach towards substituted mannose derivatives, D-Glc, D-Gal, L-Fuc and lactose. 
Soulère et al24 have also recently shown that using a PIII tri-O-allyl phosphite/I2 system, in 
place of PV diallyl chlorophosphate, successfully synthesised β-1-phosphate derivatives of 
per-O-acyl D-Glc and D-Gal with comparable yields and selectivity. 
 Fujimoto et al25 used a Mitsunobu approach to install an anomeric β-1-phosphate in 
their synthesis of protected D-glycero-D-manno-heptose-1,7-bisphosphate 24 (Scheme 6). 
The group used dibenzylphosphate as the nucleophile with a DEAD/Et3N/nBu3P reagent 
combination, obtaining 24 in good yield (56%), although with only a marginal anomeric 
selectivity (2:3, α:β). At the same time the group of Zamyatina26 were also effecting a 
synthesis of alternatively protected D-manno-heptose 23, where the workers here chose to use 
a slow addition (0.5 equiv./h) of diphenyl phosphorochloridate to achieve better anomeric 
selectivity, delivering 23 (1:4, α:β) in 51% yield (Scheme 6). 
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Scheme 6. Synthetic approaches of Zamyatina and Fujimoto towards D-glycero- D-manno-heptose-1,7-
bisphosphates 23 and 24. i) DMAP, DCM, rt; ii) DIAD, nBu3P, Et3N, DCM, rt. 
 
4. Chemical synthesis of sugar-nucleotides 
 
4.1. Pyrophosphorylation approaches 
 
 The second half of this mini-review focuses on developments in the coupling of 
sugar-1-P’s with activated NMP derivatives. The seminal work of Khorana27 is still widely 
applied, alongside Wong’s 1-H-tetrazole modification.28 However, exciting advances beyond 
this classical phosphomorpholidate strategy have been made: a notable example being 
developments in phosphorimidazolide strategies.20,23,29,30 A summary of the general approach 
for coupling NMP’s with sugar-1-Ps is shown in Figure 3, alongside some of the challenges 
inherent to their chemical synthesis.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Summary of NMP activation and considerations for diphosphate formation. LG = phospho-leaving 
group such as morpholine. X = sugar-nucleotide counter-ion; most commonly the di-Na+ form is isolated (and 
stored) using an appropriate anion exchange resin.  
O
Base
ROH
OP
O
LG
OH
O
O P
O
O
O N
NN
N
NH2
NH
NN
N
O
NH2
N
N
NH2
O
NH
N
O
O
NH
N
O
O
O
Base
ROH
OP
O
O
O
O
O P
O
O
Sugar-nucleotide 
formation
● solvent
● solubility
● counter-ions
● activator
● catalyst
● isolation
R = H for T
R = OH for U, C, A, G
Base
A G
TUC
LG Yield?
2X
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4.1.1. Pyrophosphorylation using phosphomorpholidates and phosphopiperidates 
 
Linhardt et al14 recently investigated the synthesis of non-natural UDP-donors and 
their use for the construction of chain terminated glycosaminoglycans (GAG’s). Their 
synthesis of UDP-4F-GlcNAc 25 and UDP-4F-GalNAc 26 mimetics required modification at 
C4, the native position for GAG chain extension. As such, C4-F pyranose monophosphates 4 
and 5 were utilised in 1-H-tetrazole catalysed pyrophosphorylation with UMP-morpholidate 
to deliver 25 and 26 in acceptable yields (Scheme 7). The group noted that purification of the 
target compounds was initially hampered by the presence of organic phosphate salts, but that 
these could be successfully removed by conversion of all phosphates to their sodium form 
and purification using BioGel PS SEC. Application of the mimetic tools demonstrated that 25 
was successfully transferred to the non-reducing terminus of heparosan tetra- and 
hexasaccharides using PmHS1 catalysis and established proof of concept for modulating 
GAG chain length with mimetic sugar-nucleotides.  
 
 
 
 
 
 
 
 
Scheme 7. Chemical synthesis of UDP-4F-GlcNAc and UDP-4F-GalNAc mimetics 25 and 26. i) UMP-
morpholidate, 1-H-tetrazole, py, rt, 3 days. 
 
Liu and co-workers17 also investigated the synthesis of mimetic sugar-nucleotides to 
study the mechanism of action of UDP-galactopyranose mutase (UGM), an important 
enzyme for pathogenic bacteria that converts UDP-Galp to UDP-Galf and, due to its absence 
in mammalian systems, is a potential target for anti-microbial therapeutic intervention.  
Their route prepared uridine 5'-diphosphate-5-fluorogalactopyranose (UDP-5F-Galp) 29 by 
applying Coward's epoxide fluoridolysis strategy.31 A synthesis starting from methyl-α-D-
galactopyranoside afforded exo olefin 27 and the pivotal fluorohydrin 28 was accessed via in 
situ epoxidation with DMDO, followed by ring opening with HF to deliver the target D-sugar 
in excess over its L-isomer (Scheme 8). Coupling of 28 with UMP-morpholidate using 1-H-
tetrazole provided 29 in 10% yield over three steps from 28. C5-F mimetic 29 was shown to 
form a substrate-co-factor adduct with reduced FAD, facilitated by UGM and hydrolysing 29. 
The key premise of a C5-F was then invoked to form a gem-fluorohydrin at C5, which 
irreversibly expelled HF, forming a C5-oxo species which prevented the reverse enzymatic 
pathway to Galp and confirmed further evidence towards the mechanism of action for UGM. 
 
 
 
 
 
 
 
Scheme 8. Chemical synthesis of UDP-5F-Gal 29 from exo olefin 27. i) Oxone, NaHCO3, MeCN:EDTA (0.4 
mM):acetone = 1:1:2, rt, 3.5 h; ii) HF, py, CH2Cl2, -78 °C, 1 h, 36% over 2 steps; iii) H2 (1 atm), 10% Pd/C, 
MeOH, rt, 3 h; iv) Dowex (HN+Bu3), H2O, 4 °C, 18 h; v) UMP-morpholidate, 1-H-tetrazole, py, rt, 3 days. 
 
O
BnO
BnO
BnO
O
HO
HO
OH
OUDP
OH
F
10% 
over 3 steps
O
BnO
BnO
OH
O P
O
BnO
F
i), ii)
36% 
over 2 steps
iii), iv), v)
*D:L = 6:1 = 28
*
27 29OBnOBn
O P
O
OBnOBn
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
To further explore UGM, the group sought to present an electrophilic group at C6 for 
potential interaction with nucleophilic active site residues. Accordingly, they demonstrated a 
first chemical synthesis of UDP-[5,6-F2]-Gal 32 starting from C5-F glycosyl phosphate 30. 
Fluorination of C6 using DAST generated the bis-fluorinated derivative 31. After removal of 
the benzyl protecting groups and conversion of the phosphorylated reagent to its nBu3NH+ 
form (increasing organic solubility) a coupling reaction with UMP-morpholidate delivered 
mimetic probe UDP-[5,6-F2]-Gal 32 in 4% yield over three steps (Scheme 9). No decrease in 
UGM activity was noted when 32 was incubated with the enzyme for up to 24 h. 
 
 
 
 
 
 
 
Scheme 9. Chemical synthesis of C-6 probe UDP-[5,6-F2]-Gal 32 i) DAST, py:CH2Cl2 (1:10), -40 °C to rt, 12 h, 
reflux, 2 h, 33%; ii) H2, 10% Pd/C, MeOH, rt, 3 h; iii) Dowex (HN+Bu3), H2O, 4 °C, 18 h; iv) UMP-
morpholidate, 1-H-tetrazole, py, rt, 3 days. 
  
Zhou’s group18 reported a synthesis of 4-substituted L-rhodinose sugar-nucleotides 
using glycosyl monophosphates and NMP-morpholidates in the presence of 1-H-tetrazole 
(Scheme 10). Deoxysugar-nucleotides are generally considered a more challenging synthetic 
target as the removal of electron-withdrawing ring hydroxyls renders the positively charged 
oxocarbenium intermediate more stable: conferring a higher propensity towards hydrolytic 
cleavage. To this end the group used their sugar-nucleotides 33-36 to conclude that the 
stability of these compounds was maximised in elevated buffer pH (≥7) at 5 oC and O-4 
substitution (TBS, Me, Ac) improved hydrolytic stability, as did the kinetically more stable 
α-form. Their work gave insight for the use of such sugar-nucleotides to probe relevant 
biological pathways and their potential for chemoenzymatic applications in natural product 
synthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10. Synthesis of 4-substituted NDP-α,β-L-rhodinose derivatives 33-36. i) UMP morpholidate or TMP 
morpholidate, 1-H-tetrazole, py, 2 days. ii) NaOMe, MeOH. 
 
The Janda group12 recently described their efficient synthetic method to an azide- 
modified sugar-nucleotide: UDP-N-azidoacetylgalactosylamine 37 (UDP-α,β-GalNAz). The 
coupling reaction of sugar-1-P 1 with UMP-morpholidate in the presence of 1-H-tetrazole as 
catalyst, followed by deacylation delivered mimetic 37 in 87% yield over 2 steps (Scheme 
11). UDP-GalNAc 37 was utilised as a tool for the development of site specific antibody drug 
conjugates, loading azide 37 onto an antibody using a recombinant galactosyltransferase and 
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then demonstrating click functionalisation with an Alexa Fluor 488 tagged alkyne 
(bibenzylcyclooctynol, DIBO). This strategy delivered a fluorescently labelled antibody drug 
conjugate and a platform to methodology towards the next generation of these materials.  
 
 
 
 
 
 
 
Scheme 11. Synthesis of UDP-α,β-GalNAz 37. i) UMP-morpholidate, 1-H-tetrazole, py; ii) Et3N, MeOH. 
 
The work reported by Janda’s group can be compared with that reported by Kahne et 
al,32 who examined the use of N-methylimidazolium chloride (NMI⋅HCl) as a catalyst for the 
synthesis of 37, instead of 1-H-tetrazole used by Janda. They concluded that NMI was 
superior in terms of activity, cost and safety and reduced the pyrophosphate coupling reaction 
time of GalNAz-1-phosphate 1 with UMP-phosphomorpholidate from three days (using 1-H-
tetrazole) to 12 h using NMI⋅HCl. They also reported that the yield of 37 was improved from 
71%28 to 83% using their system (Scheme 12). The authors suggested that the role of NMI 
could be that of a nucleophile as well as an acid, indicating that the electronically neutral 
phosphomorpholidate could be substituted by NMI to form a cationic phosphor-N-
methylimidazolide intermediate. Upon addition of NMI they supportively observed a 
downfield shift in the 31P NMR resonance of UMP-morpholidate.  
 
 
 
 
 
 
 
 
 
Scheme 12. Chemical synthesis of UDP-GalNAz 37 using NMI in place of 1-H-tetrazole. i) NMI⋅HCl, UMP-
morpholidate, DMF, 12 h; ii) NaOMe, MeOH. 
 
Following their description of a new class of allosteric galactosyltransferase 
inhibitors33,34 and a requirement to further develop the robustness of the synthetic protocols 
that afford essential precursors thereto, Wagner et al35 investigated the synthesis of 5’’-
substituted UDP-sugars using a UMP-phosphoromorpholidate and NMI as promoter, as 
developed by Kahne.32 Pleasingly, the group could apply the results of this work for their 
synthesis of both 5’’-I-UDP-Gal 38 and 5’’-I-UDP-GlcNAc 39 in good yields using DMF as 
solvent and with a reaction time of only 8 h (Scheme 13). Subsequent Suzuki-Miyaura 
coupling with 5-formylthien-2-yl boronic acid was successful for both 38 and 39 and allowed 
the biological evaluation of sugar-nucleotide mimetics 40 and 41 against the GlcNAc 
transferase GnT-V. The group have also used a phosphomorpholidate/1-H-tetrazole approach 
to access 5’’-substituted-UDP-Gal mimetics and an anomeric C-glycosidic analogue.36 
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Scheme 13. Synthesis of 5-substituted UDP-Gal 40 and UDP-GlcNAc 41. i) NMI⋅HCl, 5’’-I-UMP-
morpholidate, DMF, 8 h, rt; ii) 5-formyl-2-thiopheneboronic acid, CsCO3, Na2PdCl4, TPPTS, H2O, 2 h, 50 °C. 
 
Additionally, the group described the first synthetic route to prepare 5’’-CF3-UDP-
Glc 42 and 5’’-CF3-UDP-Gal 43 directly from the corresponding 5’’-unsubstituted UDP-
sugars in a one-step reaction (Scheme 14).37 
 
 
 
 
 
 
 
 
 
Scheme 14. Synthesis of 5’’-CF3-UDP-Glc 42 and 5’’-CF3-UDP-Gal 43. i) NaSO2CF3, tBuOOH, H2O. 
 
 Sun et al13,38 developed a novel PV-N activation strategy based on the excellent 
reactivity of a phosphoropiperidate/4,5-dicyanoimidazole (DCI) system which shortened the 
reaction times of pyrophosphorylation significantly, from days to 6-8 hours, to afford a series 
of 6-deoxy-L-sugar nucleotides in 70-85% isolated yields. The group first synthesised 
protected nucleoside 5'-phosphoropiperidates via phosphitylation of protected nucleotides 44 
and 45 with benzyl N,N-diisopropylchlorophosphoramidite, followed by 1-H-tetrazole 
catalysed hydrolysis and oxidative coupling with piperidine using CCl4/Et3N, to afford 
nucleoside 5'-phosphoropiperidates 46 and 47 in excellent isolated yields over four 
consecutive steps (Scheme 15). 
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Scheme 15. Chemical synthesis of uridine-5'-phosphoropiperidates. i) (iPr)2NP(OBn)Cl, Et3N, CH2Cl2, 20 °C, 
30 min; ii) 1-H-tetrazole, H2O, MeCN, 20 °C, 30 min; iii) CCl4, Et3N, piperidine, MeCN, 0-20 °C, 30 min; iv) 
H2, Pd/C, DMF, 3 h. 
  
Using a control experiment with UMP 5’-phosphoromorpholidate, the group showed 
that the reactivity of their piperidate analogues 46 and 47 reduced the time required for 
pyrophosphorylation from 28 days to 5 days using 1-H-tetrazole promotion, suggesting that 
the higher pKaH of piperdine (relative to morpholine) increased the rate of acid promoted 
activation required for reaction. They then sought to screen a series of weakly acidic 
activation systems, to further reduce the reaction times associated with using 1-H-tetrazole. 
Of the compounds investigated, DCI and N-methylimidazolium chloride showed the best 
reduction in comparable reaction time (12 h) with similar yields, but the lower hydroscopicity 
and better solubility in organic solvents prompted them to favour DCI. The uridine-5'-
phosphoropiperidates were then coupled with 6-deoxy-L-sugar-1-phosphates 2 and 3 using 
DCI as activator. A representative example to deliver UDP-α-L-rhamnose 48 is shown in 
Scheme 16. This work suggests that DCI-promoted-nucleoside phosphoropiperidate 
pyrophosphorylation is a system that improves upon more traditional approaches, however, 
its general applicability across a broader substrate scope is still to be established.  
 
 
 
 
 
 
Scheme 16. PV-N activation method for the synthesis of UDP-6-deoxy-L-rhamnose 48. i) uridine-5'-
phosphoropiperidate, DCI, DMF, 30 oC, 6 h. 
 
Jacobson and co-workers39
 
recently synthesized a range of UDP-α-D-Glc derivatives 
to build an SAR profile and probe the physiological function for endogenous ligand binding 
to the P2Y14 receptor: a ligand-gated nucleotide signaling protein that plays a role in the 
neuroimmune system. The group synthesized several derivatives to probe the effect of 
modification on the heterocyclic U base, ribose ring and Glc residue. When focusing upon 
Glc, they constructed several deoxy-fluoro mimetics, GlcA and C-2 or C-6 linked sugar-
nucleotides. In most examples, the group adopted the Khorana-UMP-morpholidate strategy 
along with the tetra-N-butyl ammonium salt form of the relevant sugar-1-P. However, in the 
case of U modified species the group switched to using CDI40 activation of the modified 
nucleoside monophosphate, followed by diphosphate coupling.  
Finally, the Liu group15 completed their impressive chemical synthesis of GDP-α-D-
octose 49 using Khorana's phosphomorpholidate approach, delivering the material in 19% 
yield (Scheme 17). 
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Scheme 17. Formation of GDP-α-D-octose 48. i) GMP-morpholidate, 1-H-tetrazole, pyridine. 
 
4.1.2. Pyrophosphorylation using phosphorimidazolides 
 
Hindsgaul et al29 established a one-pot synthetic approach to form sugar-nucleotides 
in water that required only a sequential addition of commercially available materials and 
could harness the crude reaction product as a donor for immediate use in glycosyltransferase-
mediated synthesis. The workers showed that reaction of DMC 49 with imidazole readily 
gave ImIm 50 and reasoned then whether 50 could subsequently activate a nucleotide 
monophosphate to its phosphorimidazolide to effect pyrophosphorylation (Scheme 18). 
 
 
 
 
 
 
 
 
 
Scheme 18. Formation of UMP-Im 52. i) Imidazole, D2O, <5min., rt (1L/mol DMC) ii) UMP disodium salt. 
 
Activation of UMP with 50 to produce UMP-Im 52 and urea was demonstrated, with 
the authors observing using 1H NMR monitoring in D2O that reaction times of longer than 1 
h led to hydrolysis of 52. They also noted that the reaction was more efficient in D2O than 
H2O, with yields of 52 in H2O only 60-70% of those observed using D2O.   
Subsequently the group examined the capability of 52 to form a series of sugar-
nucleotides 53-56 (Scheme 19). Finally, they utilised the crude and chemically benign 
reaction solutions containing the sugar-NDP as requisite donors in a series of 
chemoenzymatic oligosaccharide syntheses. Overall, this work aimed to offer a solution for 
the production and utilisation of sugar-nucleotides for those without a prior expertise in the 
manipulation of sugar protecting groups and in performing moisture sensitive reactions. All 
the reagents are commercially available and provided the timing of their addition to the 
reaction is carefully monitored, the desired sugar-nucleotides can be accessed and used 
immediately as requisite donors. The Lowary group20 has successfully adopted this procedure 
to synthesise UDP-GalfNAc and UDP-GalfN3, reporting both sugar-nucleotides in modest 
yields (16% and 23% respectively) although these were comparable to previously reported 
yields for similar substrates. 
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Scheme 19. Formation of sugar-nucleotides 53-56 using the ImIm method. Yields shown are isolated following 
ion-exchange chromatography purification. i) 52, D2O, 1 h, 37 oC ii) Sugar-1-P.  
  
 Jemielity’s group30 described a protecting group free, magnesium chloride-promoted 
synthesis of sugar-nucleotides from the corresponding nucleoside 5'-phosphorimidazolides 
and sugar 1-Ps in DMF (Scheme 20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 20. Proposed model for MgCl2 promoted pyrophosphate formation and an example for the synthesis of 
GDP-α-D-Glc 57 i) DMF, rt. Nuc = nucleotide. 
 
Working on a consensus that phosphorimidazole-directed sugar-nucleotide synthesis 
is not accelerated by acid catalysis (i.e. 1-H-tetrazole), the group investigated the use of 
Lewis acid-promoted pyrophosphorylation. Their work demonstrated improvements to sugar-
nucleotide formation as follows: the addition of a metal chloride (ZnCl2 or MgCl2) 
significantly improved the solubility of the reagents, which otherwise are generally poorly 
soluble in DMF; the Lewis acid acting as a catalyst, activating imidazole as a leaving group 
and coordinating both reaction partners to form the diphosphate. The optimal reaction rate 
enhancement was achieved using 2 to 4 equivalents of MgCl2 and any further addition 
retarded the rate, possibly through excessive coordination of the sugar-1-P, by Mg2+, 
decreasing its nucleophilicity.  
They applied their technology to a range of different nucleoside 5’-
phosphorimidazolides (A, G and U-containing) and sugar-1-P pairings (1-Glc, 1-Gal, 1-Fuc) 
obtaining good isolated yields (63-92%) and observing a significant reduction in reaction 
times (as low as 10 min. for GDP-α-D-Glc 57, Scheme 20) on small scale. Notably, when the 
scale was increased, to 100 mg for 57, the reaction time increased to 3 h, suggesting that the 
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reaction concentration and homogeneity for sugar-nucleotide formation is crucial for access 
to larger amounts of these materials.  
This method was successfully adopted by Vincent et al23 for their synthesis of ADP-
6-azido-6-deoxy-β-D-mannose (in 90% yield) and for construction of sulfonylated 
phosphono-exo-glycal sugar-nucleotide mimetics 58 and 59 (Scheme 21).41 Here the authors 
noted that the Lewis acidic coupling conditions promoted an isomerisation of the exo-double 
bond in 59, delivering the mimetic sugar-nucleotide as a separable E/Z mixture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 21. Synthesis of sulfonylated phosphono-exo-glycals of UDP-Galf 58 and 59. i) uridine-5’-
phosphorimidazolide, MgCl2, DMF, rt, 16 h. 
 
Taylor et al42 reported a rapid and high yielding approach for preparing sugar-
nucleotides 61-64 which obviated the commonly encountered protection/deprotection 
requirements of the donor and acceptor (Scheme 22). Sulfonylimidazolium salt 60 was used 
as the key reagent to activate the NMP component before reaction with a sugar-1-P. The 
authors reasoned that reaction between the negatively charged phosphate moiety and the 
positively charged sulfonylimidazolium salt afforded the donor before any competing 
reaction with other nucelophilic substrate functional groups. They also suggested that the 
coupling step could proceed either via a mixed P/S anhydride intermediate or an imidazolium 
species formed from initial reaction of 60 with a NMP, followed by substitution by NMI. 
Symmetrical dinucleoside diphosphate formation via dimerization was suppressed by using 
DIPEA instead of NMI and the authors also commented that any unreacted NMP could be 
removed after pyrophosphorylation using alkaline phosphatase, improving purification 
efficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 22. Synthesis of GDP- and TDP-Gal/Glc 61-64 using sulfonylimidazolium salt 60. i) DIPEA, DMF, rt, 
1 min. ii) MgCl2, rt, 0 °C, 30 min. 
O
OH
OH
HO
HO 16%
P
SO2Me
OH
O OH
O
OH
OH
HO
HO
P
SO2Me
OHO
OH
i) O
OH
OH
HO
HO
58
P
SO2Me
OUMP
O OH
i) O
OH
OH
HO
HO
59 (+58 1:1, Z/E)
P
SO2Me
OUMPO
OH
21%
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
In Table 1, we summarise the variety of activation methods for nucleoside PV monophosphate 
derivatives and their use in sugar-nucleotide synthesis. 
 
X =  Additive 
/Activator 
Target sugar-nucleotide Yield 
(%) 
Ref. 
 
 
 
 
 
 
 
 
 
 
UDP-4-F GlcpNAc 
UDP-4-F GalpNAc 
UDP-5-F Galp 
UDP-[5,6-F2] Galp 
U/TDP-4-substituted α,β-L-
rhodinoses 
UDP-α,β-GalpNAz 
UDP-α-D-Octose 
5’-I-UDP-Galp 
61 
55 
10* 
4$ 
8-34 
 
87 
19 
42 
Linhardt14 
Linhardt14 
Liu17 
Liu17 
Zhou18 
 
Janda12 
Liu15 
Wagner36 
 
 
 
 
 
UDP-L-Rhap/Talp 
dTDP-L-Rhap/Talp 
70-75 
70-75 
Sun13 
 
 
 
 
 
UDP-Glcp 
UDP-Galp 
GDP-Manp 
ADP-Glcp 
UDP-GalfNAc 
UDP-GalfN3 
43 
35 
23 
32 
16 
23 
Hindsgaul29 
″ 
″ 
″ 
Lowary20 
 
 
 
MgCl2 
 
 
 
 
 
ZnCl2 
ADP-Glcp 
GDP-Glcp 
UDP-Glcp 
UDP-Galp 
GDP-β-Fucf 
ADP-6-N3-β-Manp 
UDP-Galf mimetics 
Dimeric ADP-ribose 
92 
85 
78 
83 
63 
90 
16-21 
79 
Jemielity 30 
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″ 
″ 
Vincent23 
Vincent41 
Hergenrother48 
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UDP-4-F-Glcp 9 ″ 
 
MgCl2 TDP-β-Glcp 
TDP-β-Galp 
GDP-β-Glcp 
GDP-β-Galp 
91 
91 
82 
82 
Taylor42 
 
Table 1. Summary of methods for pyrophosphate formation used activated PV-N/O systems. 
*
 3 steps, $ 2 steps. 
 
4.1.3. Pyrophosphorylation using activated phosphate esters 
 
Meier et al43 recently utilised their cycloSal technology44,45 on solid-support (Scheme 
23), immobilising cycloSal-nucleotides via a succimidyl tether (through the furanose C3’-
OH) onto an amino-methyl polystyrene resin. In a second step, the target molecules were 
delivered through reaction of the immobilized cycloSal-triester with a series of nucleophilic 
phosphate sources, followed by the cleavage from the resin. This technology provided a 
general access to nucleoside di- and triphosphates, sugar nucleotides and dinucleoside 
diphosphates. Their method delivered the materials in high overall purity, as the impurities 
from the phosphate nucleophile (which are generally problematic to remove via RP-
chromatographic or ion-exchange systems) could be removed prior to cleavage from the 
resin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 23. Generic representation of immobilised cycloSal nucleotides (2-deoxy system shown). 
 
To access NDP-sugars the group demonstrated synthesis of TDP-β-D-glucose 65, 
UDP-β-D-glucose 66 and TDP-α-D-galactose 67 (Scheme 24). Following cleavage from the 
resin compounds 65-67 were isolated in very good purity (78% for 65 and 66). In the case of 
TDP-α-D-galactose 67 the isolated purity was lower (43%) as the group observed that the 
conditions used to effect resin cleavage caused the formation of the 1,2-cyclic phosphate 
derivative of α-Gal and TMP. 
The group also recently extended their previously reported solution-phase cycloSal 
methodology44,45 to access rare and non-natural NDP-sugars, including those containing 
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glucose-6-sulfate, L-galactose and 2-fluoro-2-deoxyglycopyranosides.16 These results, along 
with synthesis using the solid phase approach to sugar-nucleotides, are summarised in Table 
2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 24. Conversion of acceptor-substituted immobilized cycloSal-NMPs into sugar-nucleotides 65-67: i) 
(Et3NH)-tetra-O-acetyl-β-D-glucosyl-1-phosphate, DMF, 4 days, rt; ii) [(nBu)4N]-tetra-O-β-D-glucosyl-1-
phosphate, DMF, 5 days, rt; iii) (Et3NH)-tetra-O-acetyl-α-D-galactosyl-1-phosphate, DMF, 4 days, rt; iv) 
CH3OH/H2O/Et3N 7:3:1, 20 h, rt.   
 
 
X =  Additive 
/Activator 
Target Sugar-NDP Yield 
(%) 
Ref. 
-- None TDP-β-D-Glcp 
UDP-β-D-Glcp  
  TDP-α-D-Galp 
UDP-α-D-sulfoquinovose  
UDP-2-F-α-D-Manp  
UDP-2-F-α/β-D-Glcp  
UDP-2-F-α/β-D-Galp  
UDP-β-L-Galp 
78 
78 
43 
48 
52 
72 
91 
63 
Meier43,16 
 
 
Table 2. Summary of sugar-nucleotides accessed using activated cycloSal phosphate ester 
systems.  
 
4.1.4. Sugar-nucleotides from nucleoside diphosphates and sugar electrophiles 
 
Daniellou and co-workers46 recently introduced a short and versatile chemical 
synthesis for both anomers of UDP-6-NHAc-6-deoxy-Galf (Scheme 25). The group were 
seeking to provide structure-function tools and potential inhibitor candidates for the 
lipophosphoglycan pathway in the parasite Leishmania, specifically concerning the activity 
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of the galactofuranosyl transferase and UGM, for which UDP-Galf is the natural substrate. To 
do this, the group utilised 2-mercaptobenzimidazole furanose donor 68 in a direct 
diphosphate-forming glycosylation with the acidic form of UDP. Whilst this reaction was 
(expectedly) not diastereoselective, both anomers, 69 and 70, of UDP-6-NHAc-6-deoxy-Galf 
could be isolated in mg quantitates using semi-preparative RP-HPLC. Interestingly, the non-
native 1,2-trans sugar-nucleotide mimetic 70 was the more proficient in retarding the growth 
of L. donovani promastigotes in vitro. 
 
 
 
 
 
 
 
 
 
Scheme 25. Synthesis of UDP-6-NHAc-6-deoxy-Galf 69 and 70. i) UDP, DMF, 0 oC, 10 min.  
 
4.1.5. Diphosphate formation using a PIII-PV approach 
 
Hergenrother et al47 applied two different diphosphate-forming approaches in their 
synthesis of dimeric ADP-ribose 74 (Scheme 26). Firstly, the group used H-phosphonate 71 
to couple with protected-AMP, an adaptation of the Atherton-Todd reaction,48 suggesting that 
pyrophosphorylation occurs once the H-phosphonate has undergone oxidative chlorination 
with NCS to afford a chlorophosphate. Attempts to repeat this methodology to install a 
second pyrophosphate within 72 were unsuccessful and the group instead used 
phosphorimidazolide conditions (CDI, ZnCl2) to effect coupling with 73, delivering dimeric 
ADP-ribose 74 in 61%, following deprotection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 26. Synthesis of ADP-ribose dimer 74. i) NCS, DIPEA, MeCN, rt 20 min.; ii) DBU, MeCN, rt, 20 
min.; iii) H2, Pd/C Et3N, tBuOH/H2O, rt, 16 h; iv) CDI, Et3N, py. rt, 2 h, then 73, ZnCl2, DMF, rt, 96 h; v) 
NH3/MeOH, 20 h, then TBAF, THF, rt, 3h. 
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 Van der Marel and Flippov utilised their earlier reported PIII-PV pyrophosphorylation 
approach10a for a solid-phase synthesis of adenosine diphosphate ribose (ADPR) dimers, 
noting an important acceleration in oxidation of the phosphite-phosphate intermediate by 
using CSO [(1S)-(+)-(10-camphorsulfonyl)oxaziridine] in place of the more commonly 
encountered tBuOOH.10b The group also applied this modification for the synthesis of mono-
ADP-ribosylated peptides10c and extended their PIII-PV approach for the synthesis of 
methylene bisphosphonates, replacing the diphosphate linking oxygen with CH2 and opening 
a route to mimetic methylene bisphosphonates of ADP, ATP, ADPR and FAD.10 
 
5. Summary and outlook 
 
 Since the last review concerning the synthesis of sugar-nucleotides, there have been 
significant developments within this key branch of synthetic carbohydrate chemistry. Of 
particular note is advance in the number of chemical methods now available to access the 
crucial precursors, sugar-1-phosphates, across a range of monosaccharide systems, inclusive 
of mimetic and rare sugars. Reaction yields have generally improved and, perhaps more 
importantly, alternate conditions delivered (to the classically acidic environment used for 
phosphate introduction), opening new avenues for pre-modification of the sugar component. 
 Towards the central sugar-nucleotide forming reaction, the use of established 
phosphomorpholidate-activation chemistry is still commonplace. Activation is frequently 
accomplished using 1-H-tetrazole, however NMI has shown promise on a small number of 
mimetic examples. The emergence of a phosphorimidazolide-activation strategy (using Lewis 
acids or DMC as activator) provides a second nucleoside monophosphate derivative which 
has proven its capability on a number of examples in several laboratories. Perhaps most 
notable with this activation method is its use to access a broader pool of nucleoside 
components (ADP, GDP, UDP), compared with the classical morpholidate strategy (UDP 
only). This observation should be taken in context however, as the most common synthetic 
sugar-nucleotide targets are UDP-hexopyranose systems; particularly non-native species 
where the inclusion of one or multiple ring fluorine atoms and heterocycle base modifications 
confirms the necessity for robust chemical methodologies to address carbohydrate-based 
tools not accessible using chemoenzymatic strategies.   
In conclusion, advances centered around PV-PV coupling chemistries mean that whilst 
a general synthetic protocol towards any sugar-nucleotide remains ever elusive, there is a 
robust and diverse body of synthetic possibilities capable of addressing access to a significant 
number of both native and mimetic structures. We hope that this key area of glycochemistry 
will continue to explore and deliver innovative new strategies for synthesising this essential 
class of biomolecule. 
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